# Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

> **NCT00499668** · NA · WITHDRAWN · sponsor: **Vanderbilt-Ingram Cancer Center**

## Conditions studied

- Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Lymphoproliferative Disorder
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Nausea and Vomiting
- Solid Tumor

## Interventions

- **DRUG:** aprepitant
- **DRUG:** ondansetron hydrochloride

## Key facts

- **NCT ID:** NCT00499668
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-08
- **Primary completion:** 2008-01
- **Final completion:** 2008-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2013-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499668, "Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00499668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*